SAN JOSE, Calif., Dec. 10 /PRNewswire/ -- Human Pheromone Sciences, Inc. (“HPS” or “the Company”) today announced today that its Board of Directors has authorized the repurchase of up to 400,000 shares of common stock, representing approximately 10% of the current shares outstanding, from time to time in the open market and private transactions. The plan sets no time limit for any repurchases. A spokesperson indicated that “the Company is committed to a long-term share repurchase program as part of an overall capital allocation that supports growth and also returns value to shareholders.”
Human Pheromone Sciences, Inc. is a technology-based company, whose proof- of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company’s results is detailed in the Company’s annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-QSB for the quarters ended March 31, 2007, June 30, 2007 and September 30, 2007, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
CONTACT: William P. Horgan, Chairman, CEO of Human Pheromone Sciences,
Inc., +1-408-938-3030
Web site: http://www.erox.com/
